Buy Belsomra (suvorexant) online without prescription
BELSOMRA tablets contain suvorexant, a highly selective antagonist for orexin receptors OX1R and OX2R.Buy Belsomra (suvorexant) online without prescription.
Suvorexant is described chemically as: [(7R)-4-(5-chloro-2-benzoxazolyl) hexahydro-7-methyl-1H-1,4-diazepin-1-yl][5-methyl-2-(2H-1,2,3-triazol2-yl)phenyl]methanone Its empirical formula is C23H23ClN6O2 and the molecular weight is 450.92. Its structural formula is: Suvorexant is a white to off-white powder that is insoluble in water.
Each film coated tablet contains 5 mg, 10 mg, 15 mg, or 20 mg of suvorexant and the following inactive ingredients: polyvinylpyrrolidone/vinyl acetate copolymer (copovidone), microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, and magnesium stearate.
In addition, the film coating contains the following inactive ingredients: lactose monohydrate, hypromellose, titanium dioxide, and triacetin. The film coating for the 5 mg tablets also contains iron oxide yellow and iron oxide black, and the film coating for the 10 mg tablets also contains iron oxide yellow and FD&C Blue #1/Brilliant Blue FCF Aluminum Lake.
Indications & Dosage
BELSOMRA® (suvorexant) is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.
DOSAGE AND ADMINISTRATION
Use the lowest dose effective for the patient.
The recommended dose for BELSOMRA is 10 mg, taken no more than once per night and within 30 minutes of going to bed, with at least 7 hours remaining before the planned time of awakening. If the 10 mg dose is well-tolerated but not effective, the dose can be increased. The maximum recommended dose of BELSOMRA is 20 mg once daily.Buy Belsomra (suvorexant) online without prescription.
Exposure to BELSOMRA is increased in obese compared to non-obese patients, and in women compared to men. Particularly in obese women, the increased risk of exposure-related adverse effects should be considered before increasing the dose [see CLINICAL PHARMACOLOGY].
Use With CNS Depressants
When BELSOMRA is combined with other CNS depressant drugs, dosage adjustment of BELSOMRA and/or the other drug(s) may be necessary because of potentially additive effects [see WARNINGS AND PRECAUTIONS].
Use With CYP3A Inhibitors
The recommended dose of BELSOMRA is 5 mg when used with moderate CYP3A inhibitors and the dose generally should not exceed 10 mg in these patients. BELSOMRA is not recommended for use with strong CYP3A inhibitors [see DRUG INTERACTIONS]. Buy Belsomra (suvorexant) online without prescription
Time to effect of BELSOMRA may be delayed if taken with or soon after a meal.
Dosage Forms And Strengths
• 5 mg tablets are yellow, round, film-coated tablets with “5” on one side and plain on the other side.
• 10 mg tablets are green, round, film-coated tablets with “33” on one side and plain on the other side.
• 15 mg tablets are white, oval, film-coated tablets with the Merck logo on one side and “325” on the other side.
• 20 mg tablets are white, round, film-coated tablets with the Merck logo and “335” on one side and plain on the other side.
No. 3062 – BELSOMRA tablets, 5 mg, are yellow, round, film-coated tablets, with “5” on one side and plain on the other side. They are supplied as follows: NDC 0006-0005-30 unit-of-use blisters of 30
No. 3063 – BELSOMRA tablets, 10 mg, are green, round, film-coated tablets, with “33” on one side and plain on the other side. They are supplied as follows: NDC 0006-0033-30 unit-of-use blisters of 30
No. 3981 – BELSOMRA tablets, 15 mg, are white, oval, film-coated tablets with the Merck logo on one side and “325” on the other side. They are supplied as follows: NDC 0006-0325-30 unit-of-use blisters of 30
No. 3982 – BELSOMRA tablets, 20 mg, are white, round, film-coated tablets with the Merck logo and “335” on one side and plain on the other side. They are supplied as follows: NDC 0006-0335-30 unit-ofuse blisters of 30
Storage And Handling
Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F), [see USP Controlled Room Temperature]. Store in the original package until use to protect from light and moisture.
Marck Sharp & Dohme Corp., a subsidiary of MERCK & CO., INC., Whitehouse Station, NJ 08889, USA. Revised: Jul 2018.Buy Belsomra (suvorexant) online without prescription
The following serious adverse reactions are discussed in greater detail in other sections:
• CNS depressant effects and daytime impairment
• Abnormal thinking and behavioral changes
• Worsening of Depression/Suicidal ideation.
Suvorexant is the generic name of the prescription drug Belsomra, which is used to treat insomnia.
Insomnia affects about 10 percent of adults in the United States, and roughly one-third of them take drugs to help with sleep.
Belsomra belongs to a group of drugs called orexin receptor antagonists. They work by altering the action of orexins, chemicals involved in the sleep-wake cycle in the brain.
The medication was approved by the Food and Drug Administration (FDA) on August 13, 2014. The first drug in its class to be approved, Belsomra is manufactured by Merck Sharp & Dohme Corp. According to the company’s website, Belsomra is expected to be available in pharmacies in early 2015.
Belsomra’s effectiveness was tested in three clinical trials involving more than 500 patients. Results showed those who took the drug fell asleep faster and spent less time awake during the night compared to those who took a placebo pill.
The drug may also be useful in treating other conditions where sleep is affected. Belsomra may play a role in helping patients with fibromyalgia, chronic fatigue syndrome, Parkinson’s disease, and ADHD.
The medication can cause drowsiness, which can affect your ability to perform activities that require alertness. This effect can continue into the next day. You should not take more than the maximum dose of 20 milligrams (mg) of Belsomra per day.
Using Belsomra may lead to dependence or abuse. You should tell your doctor if you have a history of alcohol, prescription drug, or street drug addiction. Keep this medication in a safe place to prevent misuse. Selling or giving away Belsomra is against the law.
You should not take the drug if you are not able to stay in bed for at least seven hours before being active again.
Alert your doctor if your insomnia symptoms worsen or do not improve within seven to 10 days of taking Belsomra. This could be an indication that a different condition could be causing your sleep problems.
It is not known whether Belsomra is safe to use in children under age 18.
Before taking Belsomra, you should tell your doctor if you have:
Lung or breathing problems
A history of narcolepsy (a condition that causes people to fall asleep at unexpected times)
A history of cataplexy (sudden muscle weakness)
A history of mental illness
Pregnancy and Belsomra
It is not known whether Belsomra will harm an unborn or nursing baby. You should tell your doctor if you are pregnant or plan to become pregnant before taking this medication.
You should also alert your physician if you are breastfeeding or plan to breastfeed.